VivoSeq
Oncology

Metastatic Renal Cell Carcinoma

8

Pipeline Programs↗

5

Active Trials↗

7

Companies Involved↗

Metastatic Renal Cell Carcinoma is an early-stage landscape with 8 programs across 7 companies. The most active players are EMD Serono, Prism Pharmaceuticals, Eisai. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

1 program

Phase 2P

Prism Pharmaceuticals

1 program

Phase 2Eisai logo

Eisai

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 3Eli Lilly logo

Eli Lilly

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

8programs
Small molecule450%
Monoclonal antibody450%

Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

5

clinical trials

Active, not recruiting3 · 60%
Recruiting2 · 40%

Clinical Trials

Trial Activity

A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03595124·15 enrolled
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT03055013·819 enrolled
REPLICA: Real Patient Life Treatment With Cabozantinib in Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic RCC: a Descriptive and Prospective Non Interventional Study.
Active, not recruiting·Ipsen logoIpsen·N/A·NCT04106349·150 enrolled
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Recruiting·NRG Oncology·Phase 2·NCT05327686·240 enrolled
A Phase 1b/2 Study of Abemaciclib Plus Cabozantinib in Immune Checkpoint Blockade-pretreated Metastatic Clear Cell Renal Cell Carcinoma
Recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT06835972·43 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)